儿童肿瘤协作组AALL0434:奈拉滨治疗新诊断T细胞急性淋巴细胞白血病的III期随机临床试验
AALL0434试验纳入1562例1-31岁新诊断T细胞急性淋巴细胞白血病患者,随机比较奈拉滨联合或不联合ABFM方案,以及C-MTX与HDMTX。奈拉滨组5年无病生存率88.2%±2.4% vs 无奈拉滨组82.1%±2.7%(P=0.029),中枢神经系统复发显著减少,毒性可接受。
要点
- 奈拉滨加入ABFM方案可改善新诊断T-ALL儿童和年轻成人的无病生存。
- 奈拉滨组5年无病生存率88.2% vs 无奈拉滨组82.1%(P=0.029)。
- 奈拉滨组中枢神经系统复发显著低于无奈拉滨组(1.3% vs 6.9%,P=0.0001)。
核心结论
- 在新诊断T-ALL儿童和年轻成人中,ABFM方案加入奈拉滨可改善无病生存,且未增加毒性。
研究设计与样本
- III期随机临床试验AALL0434,2007至2014年纳入1562例可评估的1-31岁新诊断T-ALL患者。
- 患者接受ABFM方案,采用2×2伪析因随机分配接受C-MTX或HDMTX。
- 中危和高危患者在诱导后随机接受或不接受六个5天疗程的奈拉滨。
- 诱导失败患者非随机分配至HDMTX联合奈拉滨。
- 有明确中枢神经系统疾病(CNS3;≥5个白细胞/μL且有原始细胞)的患者接受HDMTX并随机接受或不接受奈拉滨。
主要发现
- 5年无事件生存率和总生存率分别为83.7%±1.1%和89.5%±0.9%。
- 随机分配至奈拉滨组(n=323)和无奈拉滨组(n=336)的T-ALL患者5年无病生存率分别为88.2%±2.4%和82.1%±2.7%(P=0.029)。
- 四臂比较中无病生存率差异显著(P=0.01),MTX和奈拉滨随机化之间无交互作用(P=0.41)。
- 表现最佳组C-MTX联合奈拉滨的5年无病生存率为91%(n=147)。
- 奈拉滨组孤立和合并中枢神经系统复发显著少于无奈拉滨组(1.3%±0.63% vs 6.9%±1.4%,P=0.0001)。
关键数值与推荐
- 奈拉滨组5年无病生存率88.2%±2.4% vs 无奈拉滨组82.1%±2.7%(P=0.029)。
- 奈拉滨组中枢神经系统复发1.3%±0.63% vs 无奈拉滨组6.9%±1.4%(P=0.0001)。
- C-MTX联合奈拉滨组5年无病生存率91%(n=147)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Nelarabine is effective in inducing remission in patients with relapsed and refractory T-cell acute lymphoblastic leukemia (T-ALL) but has not been fully evaluated in those with newly diagnosed disease. PATIENTS AND METHODS: From 2007 to 2014, Children's Oncology Group trial AALL0434 (ClinicalTrials.gov identifier: NCT00408005) enrolled 1,562 evaluable patients with T-ALL age 1-31 years who received the augmented Berlin-Frankfurt-Muenster (ABFM) regimen with a 2 × 2 pseudo-factorial randomization to receive escalating-dose methotrexate (MTX) without leucovorin rescue plus pegaspargase (C-MTX) or high-dose MTX (HDMTX) with leucovorin rescue. Intermediate- and high-risk patients were also randomly assigned after induction to receive or not receive six 5-day courses of nelarabine that was incorporated into ABFM. Patients who experienced induction failure were nonrandomly assigned to HDMTX plus nelarabine. Patients with overt CNS disease (CNS3; ≥ 5 WBCs/μL with blasts) received HDMTX and were randomly assigned to receive or not receive nelarabine. All patients, except those with low-risk disease, received cranial irradiation. RESULTS: The 5-year event-free and overall survival rates were 83.7% ± 1.1% and 89.5% ± 0.9%, respectively. The 5-year disease-free survival (DFS) rates for patients with T-ALL randomly assigned to nelarabine (n = 323) and no nelarabine (n = 336) were 88.2% ± 2.4% and 82.1% ± 2.7%, respectively (P = .029). Differences between DFS in a four-arm comparison were significant (P = .01), with no interactions between the MTX and nelarabine randomizations (P = .41). Patients treated with the best-performing arm, C-MTX plus nelarabine, had a 5-year DFS of 91% (n = 147). Patients who received nelarabine had significantly fewer isolated and combined CNS relapses compared with patients who did not receive nelarabine (1.3% ± 0.63% v 6.9% ± 1.4%, respectively; P = .0001). Toxicities, including neurotoxicity, were acceptable and similar between all four arms. CONCLUSION: The addition of nelarabine to ABFM therapy improved DFS for children and young adults with newly diagnosed T-ALL without increased toxicity.
引用
- Dunsmore KP, Winter SS, Devidas M, et al. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2020. PMID: 32813610. doi:10.1200/JCO.20.00256
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。